Given its significant hedge fund backing and attractive upside potential, Stereotaxis, Inc. (NYSEAMERICAN:STXS) is one of the most promising robotics stocks. Stereotaxis, Inc. (NYSEAMERICAN:STXS) is ...

ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial ...

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial ...

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE)-- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today ...

Stereotaxis is looking to become a dominant player in the endovascular market with the acquisition of Robocath. The deal includes an upfront payment of $20 million, and additional contingent payments ...

The latest price target for Stereotaxis (AMEX:STXS) was reported by Lake Street on March 5, 2024. The analyst firm set a price target for $4.00 expecting STXS to rise to within 12 months (a possible ...

Fischel reiterated guidance of “double-digit revenue growth for the full year 2025 with system revenue in any given quarter fluctuating between approximately $2 million to $3 million and recurring ...

Development of next generation robotically-navigated magnetic ablation catheter fully owned by Stereotaxis Catheter designed to enhance patient care, improve therapy delivery, simplify catheter ...

ST. LOUIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO ...